Your clinician will determine whether treatment is appropriate for you based on your medical history and goals
The Glp-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice
Blood Sugar Control: Comparable Results For patients with type 2 diabetes, both FDA-approved oral and injectable semaglutide effectively reduce hemoglobin A1C levels
These effects help regulate blood sugar and make you feel fuller for longer, resulting in reduced calorie intake and subsequent weight loss
Clinical trials showed continued weight loss through 72 weeks, with the bulk of results occurring in the first 40 weeks
They are now commonly used when: Metformin alone is no longer enough Weight gain is contributing to worsening glucose control There is a need to minimise hypoglycaemia risk Someone has existing cardiovascular disease or multiple risk factors For many people, GLP-1 therapy can delay or reduce the need for insulin, or allow insulin doses to be kept lower and safer
